Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report)'s share price was up 4.1% on Monday . The stock traded as high as $6.09 and last traded at $6.09. Approximately 121,359 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 378,964 shares. The stock had previously closed at $5.85.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded shares of Dominari from a "sell" rating to a "buy" rating in a research note on Saturday, August 16th.
Read Our Latest Analysis on DOMH
Dominari Trading Down 5.7%
The company's fifty day moving average is $5.69 and its 200-day moving average is $5.25. The firm has a market capitalization of $101.94 million, a P/E ratio of -2.77 and a beta of 0.75.
Dominari (NASDAQ:DOMH - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($1.02) earnings per share for the quarter. Dominari had a negative net margin of 36.01% and a negative return on equity of 94.32%. The company had revenue of $34.10 million during the quarter.
Dominari Announces Dividend
The firm also recently disclosed a special dividend, which will be paid on Friday, September 26th. Stockholders of record on Wednesday, September 3rd will be paid a $0.22 dividend. The ex-dividend date is Wednesday, September 3rd.
Institutional Investors Weigh In On Dominari
A number of hedge funds have recently made changes to their positions in DOMH. Connective Capital Management LLC bought a new position in shares of Dominari in the 2nd quarter valued at about $1,446,000. PFG Investments LLC bought a new position in Dominari during the 1st quarter worth approximately $566,000. Geode Capital Management LLC boosted its stake in Dominari by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock worth $361,000 after acquiring an additional 1,866 shares during the last quarter. Jane Street Group LLC bought a new position in Dominari during the 2nd quarter worth approximately $158,000. Finally, Magnus Financial Group LLC bought a new position in Dominari during the 2nd quarter worth approximately $136,000. Institutional investors and hedge funds own 42.48% of the company's stock.
About Dominari
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Recommended Stories
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
